EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case



Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case



Revista Medica de Chile 133(11): 1349-1354



We report a 23 years old female who presented a second episode of thrombotic thrombocytopenic purpura (TTP). She was treated with fresh frozen plasma infusions and 14 plasma exchange (PE) sessions without response. Therefore a second-line therapy was started, associating a weekly cycle administration of vindesine (Vds) 2 mg/m2 and rituximab (R) 375 mg/m2. Five cycles of this association plus one cycle of R exclusively, were administered. After the third course, biological signs of improvement were observed and complete normalization of blood cell counts and other specific parameters was seen after 8 weeks. From the beginning of her second relapse we detected a severe deficit (<5%) in von Willebrand-cleaving factor (ADAMTS13) associated to the presence of ADAMTS13 inhibitors. The combined treatment induced an improvement in ADAMTS13 values without detectable inhibitors. After 21 months of follow-up the patient was well, without signs of relapse but ADAMTS13 values were still under normal, which may be an unfavorable prognostic factor. PE is the treatment of choice for acquired idiopathic TTP, but for refractory cases or TTP cases with severe ADAMTS13 values/high inhibitor titers, PE associated to an immunosuppressive treatment should be considered.

(PDF emailed within 0-6 h: $19.90)

Accession: 050444504

Download citation: RISBibTeXText

PMID: 16446859

DOI: /S0034-98872005001100011



Related references

Case report; successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 102(1): 147-149, 2013

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. American Journal of Hematology 78(1): 49-54, 2004

Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review. Pediatric Critical Care Medicine 12(2): E90-E93, 2011

Successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura refractory to plasma exchange. Japanese Journal of Clinical Hematology 51(2): 127-131, 2010

Successful Treatment with Rituximab in a Patient with Refractory Thrombotic Thrombocytopenic Purpura. Nihon Naika Gakkai Zasshi 102(1): 147-149, 2013

Successful Treatment of Severe and Refractory Thrombotic Thrombocytopenic Purpura with Early Rituximab Administration. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 106(1): 99-106, 2017

Successful treatment with rituximab of a patient with coincident acquired hemophilia A and thrombotic thrombocytopenic purpura. Japanese Journal of Clinical Hematology 56(11): 2318-2323, 2016

Successful treatment of refractory idiopathic thrombocytopenic purpura and neutropenia with the monoclonal antibody, rituximab. Indian Journal of Hematology & Blood Transfusion 28(2): 114-116, 2013

Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome. International Journal of Hematology 90(2): 174-176, 2009

Refractory thrombotic thrombocytopenic purpura associated with primary Sjogren syndrome treated with rituximab: a case report. American Journal of Therapeutics 21(2): E56-E60, 2014

Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver International 26(5): 625-629, 2006

Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Medical Weekly 137(37-38): 518-524, 2007

Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura. Journal of Thrombosis and Thrombolysis 34(3): 416-418, 2013

Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 50(12): 2753-2760, 2011

Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy. International Journal of Hematology 104(2): 228-235, 2016